See more : Sterling Infrastructure, Inc. (STRL) Income Statement Analysis – Financial Results
Complete financial analysis of Greenwich LifeSciences, Inc. (GLSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Greenwich LifeSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Golden Rock Global Plc (GCG.L) Income Statement Analysis – Financial Results
- MetaStat, Inc. (MTST) Income Statement Analysis – Financial Results
- Pantheon International PLC (PIN.L) Income Statement Analysis – Financial Results
- EQ Energy Drink, Inc. (EQLB) Income Statement Analysis – Financial Results
- Santeon Group, Inc. (SANT) Income Statement Analysis – Financial Results
Greenwich LifeSciences, Inc. (GLSI)
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| Gross Profit | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.70M | 6.48M | 3.56M | 1.06M | 2.61M | 1.27M | 1.22M |
| General & Administrative | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 346.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Cost & Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Interest Income | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| EBITDA | -9.32M | -8.04M | -4.59M | -1.86M | -3.42M | -1.69M | -1.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.33M | -8.04M | -4.60M | -1.86M | -3.43M | -1.69M | -1.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -8.89M | -7.83M | -4.57M | -1.86M | -3.43M | -1.69M | -1.57M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -215.02K | -27.37K | -832.00 | 3.00 | -157.53K | 3.00 |
| Net Income | -8.89M | -7.61M | -4.54M | -1.86M | -3.43M | -1.69M | -1.57M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| EPS Diluted | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| Weighted Avg Shares Out | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
| Weighted Avg Shares Out (Dil) | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference
Greenwich LifeSciences Set to Join Russell 2000® Index
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Set to Join Russell 2000® Index
Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer Recurrence
Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming GP2 Treatment is Well Tolerated
Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports